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Abstract
Over the past decade, it has become evident that the
microbiome is an important environmental factor that
affects many physiological processes, such as cell prolifer‐
ation and differentiation, behaviour, immune function and
metabolism. More importantly, it may contribute to a wide
variety of diseases, including cancer, inflammatory
diseases, metabolic diseases and responses to pathogens.
We expect that international, integrative and interdiscipli‐
nary translational research teams, along with the emer‐
gence of FDA-approved platforms, will set the framework
for microbiome-based therapeutics and diagnostics. We
recognize that the microbiome ecosystem offers new
promise for personalized/precision medicine and targeted
treatment for a variety of diseases.
The short course was held as a four-session webinar series
in April 2015, taught by pioneers and experts in the
microbiome ecosystem, covering a broad range of topics
from the healthy microbiome to the effects of an altered
microbiome from neonates to adults and the long term
effects as it is related to disease, from asthma to cancer. We
have learned to appreciate how beneficial our microbes are
in breaking down our food, fighting off infections and
nurturing our immune system, and this information
provides us with ideas as to how we can manipulate our
microbiome to prevent certain diseases. However, given
the variety of applications, there are scientific challenges,
though there are very promising areas in reference to the
clinical benefits of understanding more about our micro‐
biome, whether in our gut or on our skin: the outlook is
bright. A summary of the short course is presented as a
meeting dispatch.
Keywords microbiome, bacteria, gut, cancer, therapy,
antibiotics, prenatal, personalized medicine, short course
1. Introduction
The human microbiome is an array of microorganisms,
commonly referred to as the microbiota, which resides in
our body and on our skin. Our body is home to about 100
trillion bacteria/microbial cells (in and on our body) and
two million microbial genes, but each of us only has about
40 trillion human cells and approximately 20, 000 human
genes. Bacterial cells alone outnumber our own by a factor
of 20. Therefore, understanding the microbial side and their
interactions with us (the host) is of critical importance for
our understanding of human biology, the variety of
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diseases as mentioned, susceptibility to infectious and
chronic disease, and even behaviour and drug responses.
The short course on the Microbiome organized by the
BioPharma Research Council and supported by InTech
Open Access Publisher was held as a four-session webinar
series in April 2015. The goal of the short course was to
provide, at an introductory and in some cases a deeper
glance, an exchange between researchers from academia in
the current stage of the microbiome in clinical and transla‐
tional research and, eventually, clinical practice. The
microbiome topics included a systems biology approach to
understanding our microbiome, a spatially explicit map,
how a mother’s biota affect physiology, and responses to
certain stresses in babies to the role of the microbiome in
cancer therapy.
2. Session 1: April 9, 2015
2.1 The Systems Biology Microbiome Approach by Rob Knight,
PhD
The first session was presented by Rob Knight, who
provided a systems biology approach/overview to under‐
standing the microbiome. He introduced the current
diversity measures used to study the microbiome including
alpha diversity, beta diversity, phylogenetic diversity, and
taxonomy diversity. For the past decade, Dr. Knight’s
laboratory focused on developing computational methods/
tools for mapping the microbiome data. He discussed the
UniFrac method that exploits evolutionary relationships to
compare different communities by using sequences to
build phylogenetic trees, and then uses the trees to cluster
the samples [1, 2].
Dr. Knight highlighted in his talk that the key is to identify
connections between microbes and different conditions
which we never thought of as being involved, including
links between obesity and colon cancer, rheumatoid
arthritis and (in mouse models) even things like autism,
depression and multiple sclerosis, and finding out which
of these conditions microbes cause — and which we can
either predict or modify with improved knowledge about
the microbial world. As an example of the potential utility
of measuring microbial diversity, Dr. Knight described
research from his group in which they sequenced gut
microbiomes and revealed whether or not someone was
obese with an accuracy greater than 90%, apparently more
accurate than DNA sequencing [3].
Dr. Knight further explained that faecal microbial samples
are a good representation of the gut microbiome and are
easy to collect. He presented figures displaying faecal
microbial samples from a wide selection of animals
clustered together based on a similar diet, gut type and
lineage using the UniFrac method [4, 5].
Dr. Knight also explained how researchers are able to
distinguish the cause-effect relationship between the
microbiome and many related diseases and conditions
using Koch’s Postulates. As an example, he described
research performed using gnotobiotics and model organ‐
isms. Through these experiments, scientists discovered that
transmissible gut microbiota can determine food intake [6,
7].
Dr. Knight described how, in a Malawian twin study,
children with kwashiorkor, or malnutrition, had different
microbes to their healthy twins despite having an identical
diet. Upon treatment with ready-to-use therapeutic foods,
the malnourished twins recovered while their microbial
gut population changed, but these effects were only short-
term. The microbes from both children in three twin pairs
were transferred to germ-free organisms to see if they lost
or gained weight. In two cases, those that received microbes
from malnourished children lost weight, indicating a
causal relationship.
Dr. Knight described a new comprehensive approach
involving culturing, gnotobiotics and metagenomics that
can help in scientifically determining the impact of our
microbiome. In this method, he discussed the methods in
which one will isolate the many strains of microbes from a
single faecal sample and grow them separately, then
mixing them to see if a specific disease phenotype emerges
from the mixture. This technique can be utilized to disprove
any hypotheses as to whether the cause of the disease
phenotype is a virus, cytokine or metabolite as opposed to
microbiota [8].
3. Session 2: April 16, 2015
3.1 Part I: “Roundup of the Microbiome News” by Winston
Patrick Kuo, DDS, DMSc, MS
Dr. Kuo gave an insightful overview of recent and exciting
discoveries in microbiome research. These discoveries
included studies on the relationship of the microbiome to
the immune system, obesity, cancer, mental health, and
drug metabolism. He discussed how the microbiome
affects us directly from birth (whether via traditional or C-
section) until we get old, and most of these microbes come
from the mother’s skin, birth canal and gut. He highlighted
in a recent publication how a microbe called Bifidobacteri‐
um has potentially beneficial effects for babies, as they are
among the first microbes to show up in a baby's intestinal
tract after birth. Studies suggest a particular type of
Bifidobacteria can prevent infections and help establish the
newborn's immune system. A single gene in the mother
called FUT2 controls the behaviour of Bifidobacterium, and
this gene works through breast milk [9].
Dr. Kuo mentions how we carry up to 2 kg of microbes in
our gut, and two thirds of our gut microbiome is unique to
each individual. But the question is: How could your gut
microbiota be influencing your health and risk of disease?
He describes how the microbes in our gut play an important
role in digestion: although sometimes the stomach and
small intestine are unable to digest certain foods the gut
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microbes assist in ensuring we get the nutrients we need.
For example, the gut bacteria help in the production of
vitamins B and K that play a major role in immune function.
Dr. Kuo highlighted the role of the gut microbiota and an
individual's risk of obesity and other metabolic conditions.
He discussed the research conducted at Cornell and King's
College where they identified a certain strain of bacteria -
Christensenellaceae minuta - that was more common in
people with a low body weight, and that the presence of
this particular strain is highly influenced by genes. He
mentioned the study was confirmed by introducing this
bacteria to the guts of mice, which then caused the animals
to gain less weight, indicating the bacteria may reduce or
prevent obesity [10, 11].
Dr. Kuo highlighted studies where the gut bacteria were
linked to cancers, where researchers discovered specific
bacteria in the intestines, Lactobacillus johnsonii, that may
play a role in the development of lymphoma [12]. He
discussed a study conducted by UK researchers that found
that a common gut bacteria called Helicobacter pylori may
cause stomach cancer and duodenal ulcers by deactivating
a part of the immune system involved in regulating
inflammation. Late last year, investigators from Mount
Sinai associated a specific combination of gut bacteria with
the development of colorectal cancer [13-16].
Dr. Kuo’s next topic was the relationship between the
microbiome and mental health. Can gut microbes alter the
metabolites associated with communication between the
gut and the brain, which interferes with brain function? He
discussed how bacteria has been shown to play a role in
producing neurotransmitters, such as norepinephrine,
serotonin, or dopamine, as well as how certain probiotic
bacteria can actually modulate the effects of neurotrans‐
mitters. He further discussed a microbiome-gut-brain
study in germ-free mice, where it was demonstrated that
the lack of gut microbes affects sociability, decreases
memory, and increases stress responses. The study showed
how specific strains of Lactobacillus rhamnosus modulate
stress, and this effect appears to be mediated through the
vagus nerve in mice [17].
Dr. Kuo discussed other recent topics related to stress and
anxiety, autoimmune and cardiovascular diseases and
drug metabolism. Dr. Kuo concluded his brief overview by
stating how we need a better understanding of microbiome
and drug interactions so that someday this will allow us to
devise strategies to improve drug efficacy and reduce side
effects. Not too far ahead, we can start manipulating and
explore potential therapeutic uses for the microbiome.
4. Session 2: April 16, 2015
4.1 Part II: “The Establishment of the Microbiome in Newborn
Infants: Challenges and New Opportunities” by Camilia Martin,
MD, MS
Dr. Camilia Martin discussed the influences of the early
establishment of the microbiome in the maternal-foetal
environment and ex-utero determinants. Dr. Martin
discussed recent studies that have challenged the dogma
that the Maternal-Foetal unit is sterile; however the
placenta has been determined to harbour its own unique
microbiome, and analysis of the first passage of stool in the
infant reveals microorganisms [18, 19]. In addition, she
mentioned the analysis of tracheal aspirates after early
postnatal intubation reveals organisms, presumably from
amniotic fluid swallowed when the infant was in utero [20].
Dr. Martin highlighted how the principle perinatal and
postnatal determinants of microbial colonization patterns
in the newborn include delivery mode, diet, hospitaliza‐
tion, and medications. Of these factors, a vaginal delivery
versus Caesarean section and breast milk versus formula
lead to a more favourable microbiome profile that contains
known commensal organisms and fewer organisms
considered to be pathogenic. In the preterm infant, the
microbial pattern is dominated by pathogenic rather than
commensal organisms due to factors unique to critically ill
populations such as exposure to indigenous hospital
organisms and to medications that are known to alter the
enteric flora, including antibiotics and H2 blockers [21].
Dr. Martin went on to discuss the medical consequences of
an altered microbiome where the establishment of an
intestinal microbiome is critical for immune ontogeny and
ongoing development of the intestinal tract. She observed
how the microbiome profile of a preterm infant appears to
have significant health consequences. Unfavourable
profiles have been linked to an increased risk of necrotizing
enterocolitis, lung disease, and sepsis [20, 22, 23]. The
microbiome patterns of older infants and children have also
been linked to atopic disease (allergies, asthma), type I
diabetes mellitus, celiac disease and obesity [24].
Martin also mentioned how an increasing awareness of the
influence of the microbiome on health and risk of disease
has already begun to change perinatal maternal and
neonatal medical practices. There is a concerted effort to
decrease the national Caesarean section rate, increase
maternal–infant skin-to-skin colonization after birth,
promote early and continued exposure to breast milk, and
reduce antibiotic and other medication exposures.
Dr. Martin went ahead to discuss strategies to protect and
restore microbial diversity. She emphasized the need to
optimize  the  influence  of  the  microbiome  on  health,
which is critical to protect and restore microbial diversi‐
ty. For the preterm infant, protecting microbial diversity
would entail  an understanding of  how current medical
practices alter the microbiome and a re-evaluation of the
implementation of these practices. Restoration of microbi‐
al diversity may include promoting dietary strategies that
are  known  to  optimize  the  intestinal  microbiome,
minimizing the use of medications known to disturb the
microbial  balance,  delivering  probiotics  (although  this
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remains  controversial  due  to  limited  well-designed
studies),  and  changing  medical  practices  to  those  that
attempt to emulate natural patterns of colonization, such
as strategies to expose the infant to vaginal flora even if
delivered by Caesarean section [25].
Dr.  Martin  concluded  by  discussing  the  challenges  in
bridging the gap between the microbiome and personal‐
ized  medicine.  She  mentioned  how  patterns  in  the
intestinal  microbiome  have  been  linked  to  specific
diseases  in  various  populations,  overlap  is  often  ob‐
served  between  cases  and  controls  in  many  of  the
measures used to define the microbiome. As a result, it
is  difficult  to  clinically  apply  these  observations  on  an
individual basis. In parallel, an individual’s microbiome
profile  can  be  distinctly  unique  from other  individuals
such  that  it  serves  as  a  fingerprint  to  that  person’s
identity. Thus, the precise nature of the influence of the
microbiome in an individual’s health can be difficult to
determine,  and  one’s  microbiome-host  relationship  can
be  quite  distinct  from another’s.  Dr.  Martin  concluded
that non-invasive omics strategies have the potential  to
increase our understanding of the unique microbial-host
interactions  bridging  the  path  to  both  personalized
medicine and applied populational health [26].
5. Session 3: April 23, 2015
5.1 Spatially Explicit Maps by Rob Knight, PhD
In  this  session,  Dr.  Knight  gave  examples  of  how
computational  methods  can  be  utilized  to  map  micro‐
biome genomic data. As an example, Dr. Knight present‐
ed  a  map  of  several  microbiome  clusters  representing
oral, vaginal, skin and faecal microbiomes from adults in
the same cultural community. Through the sequence of
maps, he demonstrated how the faecal microbiome of an
infant  begins  with  a  composition  identical  to  their
mother’s vaginal or skin microbiome, and after 2.5 years
ends with a composition similar to that of an adult faecal
microbiome [27].
As another example, Dr. Knight discussed a study involv‐
ing spatially explicit maps that illustrated the distribution
and diversity of the bacteria on kitchen surfaces. Bacterial
samples from four kitchens were tested and averaged. The
resulting maps demonstrated relatively high abundances
of Campylobacter on the stove exhaust fans, Salmonella on
stoves and sinks, Clostridium on the cabinets and E. coli on
the refrigerator draws. The researchers also differentiated
bacteria based on particular sources including skin,
produce and faucet water. In relatively high abundance,
bacteria derived from the skin were found on trashcans,
produce bacteria was found on the stove and counter, and
faucet water bacteria was found on faucets. This study
emphasizes implications for bacterial survivability, growth
and transmission within the kitchen [28].
Dr. Knight believes there is a better way to illustrate the
data from such studies than is currently available, and
suggests a more spatially explicit approach. Researchers in
his lab were able to map the microbial communities of one’s
face on a map of their face and correlated the different
colours to each area of the face based on the composition/
make-up of its microbiome.
Dr. Knight highlighted how another emerging and intri‐
guing area of research is establishing and validating the
relationships between the metabolome and the micro‐
biome. He discussed how researchers have created micro‐
bial and metabolite maps of the whole human body using
mass spectroscopy data: by mapping the metabolites and
microbiomes onto the human body, researchers can
hypothesize which microbes are performing the biotrans‐
formations that use or produce those metabolites.
Dr. Knight mentioned that infection by microbial patho‐
gens, such as MRSA or Clostridium difficile, is highest in a
hospital environment. The ultimate goal of the Human
Microbiome Project is to reduce the nosocomial infection
rate of hospitals through improved disinfection measures
and in order to create and support such measures; several
factors were studied to determine if they had significant
influence on the microbial community and rate of microbial
succession within the hospital. These factors included
human demographics, physical conditions such as temper‐
ature and humidity, building materials, patient microbiota,
duration of patient occupancy, patient room and nurse
station usage, and the composition and diversity of an
existing microbial community derived from previous
occupants. In total, 84 different variables were considered.
The results will be published in the near future.
6. Session 4: April 30, 2015
6.1 Part I: Microbiome and Cancer Therapy by Romina
Goldszmid, PhD
Dr. Romina Goldszmid discussed how mammals live in
partnership with a rich commensal microbiota on their
bodies’ epithelial surfaces. This partnership is critical for
tissue formation, metabolism and the development and
function of the innate and adaptive resistance. The micro‐
biota are also closely linked to cancer development both
locally (e.g., colorectal carcinoma) and at distant sites
(mammary carcinoma, lymphoma). She discussed how
recent studies demonstrated that disruption of the com‐
mensal gut microbiota impairs the response of subcutane‐
ous cancers to CpG ODN-immunotherapy and platinum
chemotherapy, and in both cases innate myeloid cells are
responsible for the impaired response, albeit through
distinct mechanisms [29]. The failure to respond to immu‐
notherapy was due to the inability of monocyte-derived
cells in the tumour microenvironment to produce pro-
inflammatory cytokines (e.g., TNF and IL-12) in response
to CpG and the subsequent necrosis needed to induce
tumour regression.
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Dr. Goldszmid further discussed how the composition of
the faecal microbiota was distinct among mice displaying
high and low TNF responses to CpG treatment, and several
bacterial species were found to either positively or nega‐
tively correlate with the TNF response. The impaired
response to platinum chemotherapy correlated with a lack
of an early genotoxic effect of the drug and reduced ROS
production by tumour infiltrating myeloid cells. These data
point to a role of microbiota in priming tumour-associated
myeloid cells to respond to immuno- and chemotherapy.
She highlights how the gut microbiota can also exert an
adjuvant effect. For example, certain chemotherapeutics
(e.g., cyclophosphamide) or the total body irradiation-
conditioning regime performed prior to adoptive T cell
transfer therapies cause damage of the gut mucosa allow‐
ing bacteria translocation into the draining lymph nodes
and increased levels of bacterial products in circulation
[30]. The translocated bacteria and their products induce
activation of antigen-presenting cells and subsequently the
priming of T cells needed for an effective anti-tumour
response [31]. Together, these findings suggest that the
composition of the commensal microbiota modulates the
response to cancer therapy, thus providing new targets and
possibilities for therapeutic intervention [32].
7. Session 4: April 30, 2015
7.1 Part II: Microbiome and Cancer Therapy by K. Leigh
Greathouse, PhD, MPH, MS, RD
Dr. Leigh Greathouse discussed that lung cancer is the
leading cancer diagnosis worldwide (1.8 million/year) and
a major health and financial burden to our healthcare
system (US$ 12.1 billion/year). It has a mortality rate higher
than that of the top three cancers combined. Epidemiolog‐
ical evidence suggests that alterations in microbial com‐
munities due to repeated antibiotic exposure are associated
with increased lung cancer risk. The microbiome consists
of bacteria, archaea, fungi, eukaryotes and viruses which
outnumber host cells ten to one and host genes >100 times.
She elaborated that several bacteria are associated with
chronic inflammation and a subsequent increased risk of
lung and colon cancer, including Mycobacterium tuberculo‐
sis (lung cancer) and Fusobacterium nucleatum (colon
cancer), a bacterium commonly isolated from inflammato‐
ry bowel disease patients and a risk factor for colon cancer.
The more virulent strains of F. nucleatum affect colon cancer
progression and increase tumour multiplicity by various
mechanisms including favouring the infiltration of tu‐
mour-promoting myeloid cells to create a pro-inflammato‐
ry environment. Colorectal carcinomas associated with a
high abundance of faecal F. nucleatum were found to have
the highest number of somatic mutations, suggesting that
these mutations create a pathogen-friendly environment.
Furthermore, the loss of p53 in enterocytes impairs the
epithelial barrier and allows infiltration of bacteria,
resulting in NF-κB signalling, which was required for
tumour progression.
Dr. Greathouse emphasized that the microbiome of lung
cancer is largely unknown. Exposure to cigarette smoke
reduces epithelial barrier function and increases suscepti‐
bility to infections. We hypothesized that somatic muta‐
tions together with cigarette smoke create a dysbiotic
microbiota that is associated with lung carcinogenesis. To
explore this hypothesis, we sequenced 16S rRNA in tissue
from lung cancer cases and controls, and lung cancer
samples in the Cancer Genome Atlas (TCGA) as validation.
Lung cancer cases could be classified by the relative
abundance of two taxa, Variovorax and Streptococcus, with
an increase in Variovorax abundance in tumours as
compared to non-tumour adjacent lung tissue. A group of
taxa were significantly associated with squamous cell
carcinoma (SCC), of which Acidovorax spp. were enriched
in smokers. Further, we observed that these taxa, including
Acidovorax, exhibit higher abundance among the subset of
SCC cases with TP53 mutations. Therefore, SCC-associated
taxa are enriched in tumours with TP53 mutations, estab‐
lishing a microbiome-gene interaction in lung cancer tissue.
8. Conclusion
Based on the session presentations, it was evident that the
microbiome translational research is quickly evolving and
that it continues to advance in all facets of science. Overall,
the short course fulfilled its goal of providing a balanced
forum of relevant content from academic researchers. The
webinar presentations are available on the BioPharma
Research Council website (http://www.biopharmare‐
searchcouncil.org). Due to the interest level in this space,
the BioPharma Research Council and the NCI will co-
sponsor a one day event at the National Cancer Institute on
September 24, 2015, entitled, “Altering the Microbiome:
Can it Impact Health?” The purpose of the meeting is to
discuss how the host microbiome can be altered and
whether such approaches can result in a positive impact on
the host.
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